AUAUniversity Podcast Series: Episode No. 80
GU Podcast (2020) - Sequencing Of Agents And Combination Of Treatment Options For Bladder Cancer
At the conclusion of this activity, participants will be able to:
- Evaluate treatment plans including the sequencing and combination of treatment options for individual patients.
- Explain best practices in MIBC and NMIBC patient selection for various treatment options.
- Facilitate discussions with patients and caregivers regarding their treatment options.
This educational series is supported by independent educational grants from:
- Astellas
- AstraZeneca
- Bristol Myers Squibb
- Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
- Merck
- Pfizer, Inc
- Sanofi Genzyme
- UroGen Pharma, Inc.